CN101152165A - Antineoplastic isoliquirtigenin tablet - Google Patents
Antineoplastic isoliquirtigenin tablet Download PDFInfo
- Publication number
- CN101152165A CN101152165A CNA2007100531477A CN200710053147A CN101152165A CN 101152165 A CN101152165 A CN 101152165A CN A2007100531477 A CNA2007100531477 A CN A2007100531477A CN 200710053147 A CN200710053147 A CN 200710053147A CN 101152165 A CN101152165 A CN 101152165A
- Authority
- CN
- China
- Prior art keywords
- isoliquiritigenin
- starch
- antineoplastic
- ethanol
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an antitumor isoliquiritigenin tablet. The isoliquiritigenin is used as an effective component to prepare antitumor tablet. The antitumor isoliquiritigenin tablet contains isoliquiritigenin, filler, adhesive, disintegrant, wetting agen and lubricant, which are proportioned according to a certain proportion. The formula is reasonable and the use is convenient. The drug combination prepared in the method has good antitumor function, good treating effects and low side effects.
Description
Technical field
The present invention relates to pharmaceutical field, more specifically relate to a kind of antineoplastic isoliquiritigenin tablet.Be applicable to human cervical carcinoma cell, prostate gland cancer cell, S
180Tumor strain, ehrlich ascites cell, people A549 lung carcinoma cell, oral cavity epidermal carcinoma KB cell, KM-12 colon cancer cell, BEL-7402 hepatoma carcinoma cell and MCF-7 breast cancer cell.
Background technology
1. tumor has become the No.1 killer who threatens human health
Tumor is one of serious threat human life's commonly encountered diseases and frequently-occurring disease, and its sickness rate increases year by year.Show nearly 1,000 ten thousand people of the annual new discovery cancer patient in the whole world according to World Health Organization's investigation.Annual because of nearly 7,000,000 people of the number of cancer mortality.Statistics shows recently, about 2,000 ten thousand people of the annual new discovery cancer patient of China, and nearly 1,500,000 people die from cancer.The death toll of cancer accounts for 1/5 of total death toll.Therefore give protection against cancer, control cancer, become an extremely urgent hardship post.
2. the method for current treatment tumor is more, but all has certain limitation
The traditional method of treatment tumor has excision, radiotherapy and chemotherapy.But, may when being diagnosed as tumor, just lose the chance of excision for a lot of patients; Then there be partial restricted and damaging to normal structure in radiotherapy; Chemistry (medicine) ubiquity cytotoxic effect, serious to liver, kidney, bone marrow and digestive system toxic and side effects especially, therefore, restricted their uses clinically greatly.Emerging interventional therapy has certain effect to primary tumor, but is difficult to tackle the metastasis of constantly distributing; Modern molecular targeted property (gene) treatment brings dawn to tumor patient, but the crosslinked and problems such as variation in body distribution, metabolic process of its vector construction, carrier and bullet are also among discussion.
3. the antitumor action of flavone compound
Flavone compound is a class polyphenolic substance, extensively is present in multiple green vegetables, fruit and the medicinal plants.In recent years, flavone compound has been subjected to paying attention to widely in the effect of keeping aspect human body normal physiological function and the disease preventing and treating.Epidemiological study shows, often take in and be rich in the vegetable of flavone compound and sickness rate (the Armstrong B that fruit can reduce cancers such as pulmonary carcinoma, colorectal cancer and breast carcinoma, Doll R.Environmental factors and cancer incidence and mortality in different countries, withspecial reference to dietary practices[J] .Int J Cancer.1975,15 (4): 617-631.).Because the anti-tumor activity of flavone compound often has characteristics such as high-efficiency low-toxicity, the many developed countries such as the U.S. are constantly at the screening operation that carries out the flavone compound antitumor action.
The discovery that flavone compound has antitumor action impels people to attempt the enthusiasm of preparation tumor chemicals from natural plants.Up to the present, result of study is challenging: (1) flavone compound suppresses cell proliferation, mainly is that cell cycle is stopped, and tumor cell is had cytotoxicity, and, the immunoregulation effect of antioxidation and forward is arranged on the contrary to normal cell avirulence and mutagenesis; (2) flavone compound promotes apoptosis of tumor cells; (3) flavone compound can suppress tyrosine protein kinase, Protein kinase C, the phosphatidylinositol 3-kinase activity in the cell signalling process; (4) flavone compound has antiinflammatory, antioxidation pressure and promotes expression of tumor suppressor gene and suppress the effect of oncogene expression.At present, the screening operation of flavone compound antitumor action is still constantly carrying out, and China is one and has the country that enriches Chinese herbal medicine resource that fully developing flavone compound is that human health service is the advantage of China.
Isoliquiritigenin is a kind of effective monomer in the Radix Glycyrrhizae, belong to flavone compound, have biological activity (Ii T such as antitumor, antiviral, free radical resisting, inhibition lipid peroxidation, Satomi Y, Katoh D, et al.Induction ofcell cycle arrest and p21CIP1/WAF1 expression in human lung cancer cells byisoliquiritigenin[J] .Cancer Lett, 2004,207 (1): 27-35; Haraguchi H, Ishikawa H, Mizutani K, et al.Antioxidative and superoxide scavenging activities ofretrochalcones in Glycyrrhiza inflata.[J] .Bioorg Med Chem, 1998,6 (3): 339-347).Foreign literature is reported in recent years, isoliquiritigenin can suppress kinds of tumor cells propagation (Kanazawa M such as pulmonary carcinoma, breast carcinoma and carcinoma of prostate, Satomi Y, Mizutani Y, et al.Isoliquiritigenin inhibits the growth ofprostate cancer[J] .Eur Urol, 2003,43 (5): 580-586; Hsu YL, Kuo PL, Chiang LC, etal.Isoliquiritigenin inhibits the proliferation and induces the apoptosis of humannon-small cell lung cancer A549 cells[J] .Clin Exp Pharmacol Physiol, 2004,31 (7): 414-418).In addition, our research also show ISL can suppress the propagation of cervical cancer cell (Zhang Jing, etc. isoliquiritigenin is to the effect of human cervical carcinoma cell inhibition of proliferation. Chinese J Pharmacol Toxicol, 2005,19 (6): 436-442).
But, up to now, do not have the preparation method of oral formulations such as isoliquiritigenin antitumor tablet or capsule to be disclosed or to use by retrieval.
Summary of the invention
The objective of the invention is to be to provide a kind of antineoplastic isoliquiritigenin tablet, it is made of by a certain percentage isoliquiritigenin, filler, binding agent, disintegrating agent, wetting agent, lubricant, and prescription rationally, easy to use, nontoxic to human body, nonirritant, safe in utilization, respond well.
Isoliquiritigenin (isoliquiritigenin, ISL), its chemical constitution is 2 ', 4 ', 4 '-trihydroxy chalcone derivative, be a kind of effective monomer in the Radix Glycyrrhizae, belong to flavone compound (I asked for an interview in chemical structural formula), have biological activitys such as antitumor, antiviral, free radical resisting, inhibition lipid peroxidation.Bibliographical information in recent years, ISL can suppress kinds of tumor cells propagation such as pulmonary carcinoma, breast carcinoma, carcinoma of prostate and cervical cancer.But, up to now, do not have the preparation method of isoliquiritigenin antitumor tablet to be disclosed or to use by retrieval.
The molecular structure of isoliquiritigenin is:
The source of isoliquiritigenin: the isoliquiritigenin wide material sources, both can chemosynthesis, also can be from Radix Glycyrrhizae separation and Extraction, and all purchase on the market.
The present invention is used to prepare the antineoplastic tablet with isoliquiritigenin.In order to realize that the present invention by the following technical solutions: this tablet is made by following raw materials by weight;
Raw material weight percentage ratio (%)
Isoliquiritigenin 10～15
Filler 71～85
Binding agent 1～8
Disintegrating agent 1～8
Wetting agent 1～6
Lubricant 1～2
Its preparation process is as follows:
1. add adjuvant: adding wetting agent mixing is made soft material add filler, binding agent and disintegrating agent respectively in isoliquiritigenin after;
2. granulate: the soft material of mixing is crossed 50-200 order nylon mesh granulate, dried 30 minutes for 70～80 ℃, cross 50-200 order ferrum sieve granulate;
3. tabletting: add the lubricant tabletting and make tablet.
Described filler is the wherein a kind of of starch, dextrin, Icing Sugar, pregelatinized Starch, lactose, glucose, microcrystalline Cellulose, calcium carbonate, calcium sulfate, calcium bicarbonate or other pharmaceutically acceptable filleies or wherein two to ten kinds or combination in any;
Described binding agent is the wherein a kind of of liquid glucose, arabic gum, gelatin, hydroxy methocel, low-substituted hydroxypropyl cellulose or other pharmaceutically acceptable binding agents or wherein two to five kinds or combination in any;
Described disintegrating agent is the wherein a kind of of cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, hydroxypropyl starch, low-substituted hydroxypropyl cellulose, citric acid, tartaric acid, anhydride, sodium bicarbonate, sodium carbonate or other pharmaceutically acceptable disintegrating agents or wherein two to nine kinds or combination in any;
Described wetting agent is water, ethanol or its combination;
Described lubricant is the wherein a kind of of magnesium stearate, Pulvis Talci, liquid Paraffin, Polyethylene Glycol or other pharmaceutically acceptable lubricants or wherein two to four kinds or combination in any.
Advantage of the present invention:
1. isoliquiritigenin wide material sources both can chemosynthesis, also can be from Radix Glycyrrhizae separation and Extraction, and market is on sale.
2. the present invention adopts conventional peroral dosage form, technology maturation, and production technology is simple.
3. the present invention adopts oral administration mode, convenient drug administration, no pain.
4. isoliquiritigenin tablet is little to the human body toxic and side effects, and is safe in utilization, and tumour inhibiting rate can reach 47.3～74.9%, and is respond well.
5. the isoliquiritigenin tablet that adopts of the present invention not only has tangible tumor-inhibiting action but also synergism and attenuation obvious.
The specific embodiment
Various details embodiment, but content of the present invention is not limited thereto fully.
| Isoliquiritigenin | Filler | Binding agent | Disintegrating agent | Wetting agent | Lubricant | |
| Embodiment 1 | 10.0％ | Starch 85.0% | Arabic gum 2.0% | Cross-linking sodium carboxymethyl cellulose 1.0% | Ethanol 1.0% | Magnesium stearate 1.0% |
| Embodiment 2 | 10.5％ | Dextrin 84.0% | Hydroxy methocel 2.0% | Carboxymethyl starch sodium 1.5% | Ethanol 1.0% | Polyethylene Glycol 1.0% |
| Embodiment 3 | 11.0％ | Starch 83.0% | Arabic gum 3.0% | Hydroxypropyl starch 1.0% | Ethanol 1.0% | Polyethylene Glycol 1.0% |
| Embodiment 4 | 11.5％ | Dextrin 81.0% | Gelatin 1.0% | Carboxymethyl starch sodium 3.0% | Ethanol 2.5% | Magnesium stearate 1.0% |
| Embodiment 5 | 12.0％ | Dextrin 78.0% | Hydroxy methocel 2.0% | Hydroxypropyl starch 4.0% | Ethanol 2.0% | Polyethylene Glycol 2.0% |
| Embodiment 6 | 12.5％ | Starch 77.0% | Arabic gum 1.0% | Hydroxypropyl starch 4.5% | Ethanol 2.0% | Magnesium stearate 1.0% |
| Embodiment 7 | 13.0％ | Dextrin 76.0% | Hydroxy methocel 3.0% | Sodium bicarbonate 3.0% | Ethanol 3.0% | Pulvis Talci 2.0% |
| Embodiment 8 | 13.5％ | Dextrin 75.0% | Gelatin 4.0% | Sodium bicarbonate 3.5% | Ethanol 2.0% | Magnesium stearate 2.0% |
| Embodiment 9 | 14.0％ | Starch 73.0% | Hydroxy methocel 2.5% | Sodium bicarbonate 6.0% | Ethanol 2.5% | Pulvis Talci 2.0% |
| Embodiment 10 | 15.0％ | Dextrin 71.0% | Gelatin 3.0% | Cross-linking sodium carboxymethyl cellulose 5.0% | Ethanol 5.0% | Magnesium stearate 1.0% |
Its preparation process is as follows:
1. add adjuvant: adding wetting agent mixing is made soft material add filler, binding agent and disintegrating agent respectively in isoliquiritigenin after;
2. granulate: the soft material of mixing is crossed 50-200 order nylon mesh granulate, dried 30 minutes for 70～80 ℃, cross 50-200 order ferrum sieve granulate;
3. tabletting: add the lubricant tabletting and make tablet.
Described filler is the wherein a kind of of starch, dextrin, Icing Sugar, pregelatinized Starch, lactose, glucose, microcrystalline Cellulose, calcium carbonate, calcium sulfate, calcium bicarbonate or other pharmaceutically acceptable filleies or wherein two to ten kinds or combination in any;
Described binding agent is the wherein a kind of of liquid glucose, arabic gum, gelatin, hydroxy methocel, low-substituted hydroxypropyl cellulose or other pharmaceutically acceptable binding agents or wherein two to five kinds or combination in any;
Described disintegrating agent is the wherein a kind of of cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, hydroxypropyl starch, low-substituted hydroxypropyl cellulose citric acid, tartaric acid, anhydride, sodium bicarbonate, sodium carbonate or other pharmaceutically acceptable filleies or wherein two to nine kinds or combination in any;
Described wetting agent is water, ethanol or its combination;
Described lubricant is the wherein a kind of of magnesium stearate, Pulvis Talci, liquid Paraffin, Polyethylene Glycol or other pharmaceutically acceptable filleies or wherein two to four kinds or combination in any.
Pharmacodynamic experiment
In order to disclose essence of the present invention, from aspects such as tumor-inhibiting action and attenuation synergistics the isoliquiritigenin preparation is carried out pharmacodynamic study in conjunction with the present invention:
(1) experiment material
1, medicine: isoliquiritigenin tablet provides lot number by Wuhan University medicine non-clinical study center: 030401; Tegafur (FT207) is produced by Jinan pharmaceutical factory, lot number: 031003; Cyclophosphamide is produced lot number: 21156-21160 by the permanent auspicious medical limited company in Jiangxi; FUFANG EJIAO JIANG is produced by Shandong Colla Corii Asini limited company, lot number: 040672.
2, animal: Kunming mouse, BALB/c mouse, SD kind rat, the male and female dual-purpose is provided credit number by Wuhan University's Experimental Animal Center: SCXK (Hubei Province) 2003-0004.
3, JEG-3 and target cell: S
180Tumor strain, ehrlich ascites cell, A
549Lung carcinoma cell, oral cavity epidermal carcinoma KB cell, KM-12 colon cancer cell, BEL-7402 hepatoma carcinoma cell and MCF-7 breast carcinoma cell strain are introduced and are gone down to posterity by Chinese medical courses in general institute medicine.
4, reagent and instrument: MTT is provided by Sigma company; 450 type microplate reader are produced by U.S. BioRad.
(2) experimental technique and result
1. inhibition test
1.1 vitro inhibition effect to multiple cancerous cell line
With isoliquiritigenin tablet 20,100,500mg.kg
-1Handle mice, preparation pastille serum; With 0.25% trypsinization, passage cell.Adjust cell concentration to 2 * 10 with RPMI-1 640 culture fluid that contain 10% hyclone
4Individual .ml
-1, the every hole of 96 well culture plates adds 100 μ l, 37 ℃, 5%CO
2Hatch 24h, abandon culture fluid, add the pastille serum of 10% filtration sterilization, 37 ℃, 5%CO
2Hatch 18h altogether, adopt mtt assay to detect cell proliferation.
The results are shown in Table 1.
Table 1. isoliquiritigenin is to the influence of different carcinoma cell strain cell growth
| Group | Dosage (mg/kg) | Suppression ratio (%) | ||||
| A549 | KB | KM-12 | BEL-7402 | MCF-7 | ||
| The different Radix Glycyrrhizae rope of blank group group | - 20 100 500 | 1.3±0.3 25.9±4.1** 55.6±3.8** 74.9±3.4** | 1.2±0.4 14.8±3.1 * 27.6±3.2 ** 47.3±4.3 ** | 1.4±0.4 15.7±2.7 * 44.5±3.9 ** 74.8±2.6 ** | 0.9±0.2 15.9±2.8 * 39.7±4.1 ** 60.9±3.2 ** | 12±0.2 27.9±3.0 ** 39.9±3.7 ** 54.88±3.2 ** |
Compare * * P＜0.01 with the blank group
Table 1 result as seen, compare with the blank group, large, medium and small three the dosage groups of isoliquiritigenin all have the obvious suppression effect to the growth of people A549 lung carcinoma cell, oral cavity epidermal carcinoma KB cell, KM-12 colon cancer cell, BEL-7402 hepatoma carcinoma cell and MCF-7 breast cancer cell, and have certain dose-effect relationship.
1.2 to S
180The inhibitory action of sarcoma strain
Get tumor cell (tumor-bearing mice abdominal cavity S
180Sarcoma cell 2 * 10
6Individual male and healthy BALB/c nude mice oxter, the random packet of being inoculated in.Began to irritate stomach on the 2nd day in the inoculation back and give isoliquiritigenin, 1 time/day, dosage is respectively 20mg.kg
-1, 100mg.kg
-1, 500mg.kg
-1, contrast gives the solvent of respective volume, continuous irrigation stomach 10 days, and eye socket is got blood when off-test, plucks tumor, claims tumor heavy.
The results are shown in Table 2.The tumour inhibiting rate of large, medium and small three the dosage groups of isoliquiritigenin is respectively 53.6%, 45.7% and 36.2% and have certain dose-effect relationship.
Table 2. isoliquiritigenin is to S
180The influence of tumor-bearing mice tumor bulk-growth
Compare * P＜0.05, * * P＜0.01 with the blank group
1.3 influence to the ehrlich carcinoma survival time of mice
Table 3 is the result show: the big or middle dosage group of isoliquiritigenin all prolongs the ehrlich carcinoma mouse storaging current, with lotus tumor group significant difference is arranged relatively; The effect of small dose group is not obvious.Three result of the tests show that all isoliquiritigenin can prolong tumor-bearing mice life cycle.
Table 3 isoliquiritigenin is to the influence of ehrlich carcinoma survival time of mice
Compare * P＜0.05, * * P＜0.01 with the normal saline group
2. attenuation synergistic test
2.1 attenuation test
Table 4 is the result show, behind the rat injection cyclophosphamide, bone marrow nucleated cell digital display work is descended, relatively reduce by 48.9% with the normal control group: and the big or middle dosage of isoliquiritigenin can obviously improve the rat marrow nucleated cell number reduction that cyclophosphamide causes, relatively has significant difference with model group.The isoliquiritigenin that big or middle dosage is described suppresses to have certain therapeutic effect to the hemopoietic function of bone marrow that chemotherapeutic causes.
Table 4 isoliquiritigenin is to the influence of cyclophosphamide rat marrow nucleated cell number
| Group | Dosage (mg/kg) | Bone marrow nucleated cell number (* 10 9/L) |
| The heavy dose of group of dosage group cyclophosphamide in normal control group cyclophosphamide-a control group cyclophosphamide+isoliquiritigenin small dose group cyclophosphamide+isoliquiritigenin+isoliquiritigenin | - - 20 100 500 | 10.26±3.29 6.69±1.18 △ 9.10±3.46 10.20±3.62* 10.65±3.83* |
Compare with the normal control group,
△P＜0.05; Compare * P＜0.05 with model control group
Table 5 is the result show, leukocyte and platelet count significantly descend behind the rat injection cyclophosphamide, and it is less that the leukocyte of the big or middle dosage group of isoliquiritigenin and platelet count reduce amplitude, compares with model control group, and the significance difference is arranged.The big or middle dosage of prompting isoliquiritigenin has antagonism preferably to leukocyte and the thrombocytopenia that cyclophosphamide causes, and can alleviate the toxic and side effects of chemotherapeutic to a certain extent.
Table 5 isoliquiritigenin is to the influence of cyclophosphamide rat peripheral blood hematological indices
| Group | Dosage (mg/kg) | WBC (×10 9/L) | Hb (g/L) | RBC (×10 12/L) | PLC (×10 9/L) |
| Normal control group model matched group isoliquiritigenin group | - - 20 100 500 | 9.89±2.09 5.30±1.50 △△ 8.21±1.99 8.60±1.81 * 9.33±1.90 ** | 135.91±5.51 122.39±8.50 △ 119.82±6.72 128.43±6.90 124.11±7.65 | 9.71±1.70 8.23±1.09 8.55±0.98 8.35±0.87 8.36±1.17 | 618.51±47.91 291.20±52.50 △△ 539.01±104.60 628.22±97.13 ** 630.79±124.81 ** |
With normal control group ratio,
△P＜0.05,
△ △P＜0.01; With the model control group ratio,
*P＜0.05,
*P＜0.05
2.2 synergism test
The results are shown in Table 6.Tumour inhibiting rate with cyclophosphamide (25mg/kg) and isoliquiritigenin (20mg/kg) group is respectively 28.3% and 29.8% separately, and unite the inhibitory rate to 72.7% of using cyclophosphamide (25mg/kg)+isoliquiritigenin (20mg/kg), compare with independent medication group, tumour inhibiting rate is significantly increased.Above result as can be seen, isoliquiritigenin share with low dose of chemotherapeutic, can improve tumour inhibiting rate, has shown the advantage of drug combination.
Table 6 isoliquiritigenin and cyclophosphamide share S
180The influence of tumor strain growth
| Group | Dosage (mg/kg) | Tumor body weight (g) | Tumour inhibiting rate (%) |
| Normal saline group cyclophosphamide group isoliquiritigenin group isoliquiritigenin+cyclophosphamide group | - 25 20 20+25 | 1.98±0.42 1.42±0.66 ** 1.39±0.70 ** 0.54±0.43 ** | - 28.3 29.8 72.7 |
Compare with the normal saline group,
*P＜0.01;
(3) conclusion
Above-mentioned experimental result shows that isoliquiritigenin not only has the effect of obvious inhibition tumor growth, and has the effect that alleviates its toxic and side effects and strengthen its tumor-inhibiting action when share with chemotherapeutic.
Claims (10)
1. antineoplastic isoliquiritigenin tablet, it is made by following raw materials by weight:
Raw material weight percentage ratio
Isoliquiritigenin 10～15%
Filler 71～85%
Binding agent 1～8%
Disintegrating agent 1～8%
Wetting agent 1～6%
Lubricant 1～2%;
Its preparation process is:
1. adding wetting agent mixing is made soft material add filler, binding agent and disintegrating agent respectively in isoliquiritigenin after;
2. granulate: the soft material of mixing is crossed 50-200 order nylon mesh granulate, dried 30 minutes for 70～80 ℃, cross 50-200 order ferrum sieve granulate;
3. tabletting: add the lubricant tabletting and make tablet;
Described filler is the wherein a kind of of starch, dextrin, Icing Sugar, pregelatinized Starch, lactose, glucose, microcrystalline Cellulose, calcium carbonate, calcium sulfate, calcium bicarbonate or other pharmaceutically acceptable filleies or two to ten kinds or combination in any;
Described binding agent is the wherein a kind of of liquid glucose, arabic gum, gelatin, hydroxy methocel, low-substituted hydroxypropyl cellulose or other pharmaceutically acceptable binding agents or two to five kinds or combination in any;
Described disintegrating agent is the wherein a kind of of cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, hydroxypropyl starch, low-substituted hydroxypropyl cellulose, citric acid, tartaric acid, anhydride, sodium bicarbonate, sodium carbonate or other pharmaceutically acceptable disintegrating agents or two to nine kinds or combination in any;
Described wetting agent is water, ethanol or its combination;
Described lubricant is the wherein a kind of of magnesium stearate, Pulvis Talci, liquid Paraffin, Polyethylene Glycol or other pharmaceutically acceptable lubricants or two to four kinds or combination in any.
2. a kind of antineoplastic isoliquiritigenin tablet according to claim 1, it is characterized in that: it is made by following raw materials by weight: isoliquiritigenin 10%, starch 85%, arabic gum 2%, cross-linking sodium carboxymethyl cellulose 1%, ethanol 1%, magnesium stearate 1%.
3. a kind of antineoplastic isoliquiritigenin tablet according to claim 1, it is characterized in that: it is made by following raw materials by weight: isoliquiritigenin 10.5%, dextrin 84%, hydroxy methocel 2%, carboxymethyl starch sodium 1%, ethanol 1%, Polyethylene Glycol 1%.
4. a kind of antineoplastic isoliquiritigenin tablet according to claim 1, it is characterized in that: it is made by following raw materials by weight: isoliquiritigenin 11.0%, starch 83%, arabic gum 3%, hydroxypropyl starch 1%, ethanol 1%, Polyethylene Glycol 1%.
5. a kind of antineoplastic isoliquiritigenin tablet according to claim 1, it is characterized in that: it is made by following raw materials by weight: isoliquiritigenin 11.5%, dextrin 81%, gelatin 1%, carboxymethyl starch sodium 3%, ethanol 2.5%, magnesium stearate 1%.
6. a kind of antineoplastic isoliquiritigenin tablet according to claim 1, it is characterized in that: it is made by following raw materials by weight: isoliquiritigenin 12.0%, dextrin 78%, hydroxy methocel 2% hydroxypropyl starch 4%, ethanol 2.5%, Polyethylene Glycol 1%.
7. according to the described a kind of antineoplastic isoliquiritigenin tablet of claim 1, it is characterized in that: it is made by following raw materials by weight: isoliquiritigenin 12.5%, starch 77%, arabic gum 1%, hydroxypropyl starch 4.5%, ethanol 3%, magnesium stearate 2%.
8. a kind of antineoplastic isoliquiritigenin tablet according to claim 1, it is characterized in that: it is made by following raw materials by weight: isoliquiritigenin 13.0%, dextrin 76%, hydroxy methocel 3%, sodium bicarbonate 3%, ethanol 3%, Pulvis Talci 2%.
9. a kind of antineoplastic isoliquiritigenin tablet according to claim 1, it is characterized in that: it is made by following raw materials by weight: isoliquiritigenin 13.5%, dextrin 75%, gelatin 4%, sodium bicarbonate 3.5%, ethanol 2%, magnesium stearate 2%.
10. a kind of antineoplastic isoliquiritigenin tablet according to claim 1, it is characterized in that: it is made by following raw materials by weight: isoliquiritigenin 14.0%, starch 73%, gelatin 3%, hydroxy methocel 2.5%, sodium bicarbonate 6%, ethanol 2.5%, Pulvis Talci 2%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100531477A CN101152165A (en) | 2007-09-06 | 2007-09-06 | Antineoplastic isoliquirtigenin tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100531477A CN101152165A (en) | 2007-09-06 | 2007-09-06 | Antineoplastic isoliquirtigenin tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101152165A true CN101152165A (en) | 2008-04-02 |
Family
ID=39254185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100531477A Pending CN101152165A (en) | 2007-09-06 | 2007-09-06 | Antineoplastic isoliquirtigenin tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101152165A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101524341B (en) * | 2009-03-20 | 2011-04-20 | 中国科学院近代物理研究所 | Use of isoliquiritigenin in preparation of auxiliary therapeutic medicine for tumor radiation therapy |
| CN104887650A (en) * | 2014-03-03 | 2015-09-09 | 陈建萍 | New use of isoliquiritigenin and derivative |
| CN104997760A (en) * | 2015-07-22 | 2015-10-28 | 苏州沪云肿瘤研究中心股份有限公司 | Double-function anti-androgen drug and uses thereof |
| CN106265611A (en) * | 2015-05-25 | 2017-01-04 | 四川大学 | The new application of isoliquiritigenin |
| CN110384690A (en) * | 2019-07-26 | 2019-10-29 | 上海中医药大学 | Isoliquiritigenin is preparing the application in anxiolytic drugs |
| CN110812384A (en) * | 2019-12-20 | 2020-02-21 | 江西中医药大学 | New medical application of effective component and derivative thereof in liquorice |
| CN115887429A (en) * | 2022-11-24 | 2023-04-04 | 广州市番禺区中心医院 | Application of isoliquiritigenin in preparing medicine for treating paclitaxel-induced liver injury |
-
2007
- 2007-09-06 CN CNA2007100531477A patent/CN101152165A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101524341B (en) * | 2009-03-20 | 2011-04-20 | 中国科学院近代物理研究所 | Use of isoliquiritigenin in preparation of auxiliary therapeutic medicine for tumor radiation therapy |
| CN104887650A (en) * | 2014-03-03 | 2015-09-09 | 陈建萍 | New use of isoliquiritigenin and derivative |
| CN106265611A (en) * | 2015-05-25 | 2017-01-04 | 四川大学 | The new application of isoliquiritigenin |
| CN104997760A (en) * | 2015-07-22 | 2015-10-28 | 苏州沪云肿瘤研究中心股份有限公司 | Double-function anti-androgen drug and uses thereof |
| CN110384690A (en) * | 2019-07-26 | 2019-10-29 | 上海中医药大学 | Isoliquiritigenin is preparing the application in anxiolytic drugs |
| CN110812384A (en) * | 2019-12-20 | 2020-02-21 | 江西中医药大学 | New medical application of effective component and derivative thereof in liquorice |
| CN115887429A (en) * | 2022-11-24 | 2023-04-04 | 广州市番禺区中心医院 | Application of isoliquiritigenin in preparing medicine for treating paclitaxel-induced liver injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008475B (en) | Application of quinolizidine in preparing tumor treatment drugs | |
| CN102166335A (en) | Ginger and long pepper composition as well as preparation method and application thereof in preparation of toxicity reducing and efficacy enhancing medicament in radiotherapy and chemotherapy of cancer | |
| CN101152165A (en) | Antineoplastic isoliquirtigenin tablet | |
| CN102091315A (en) | Ginger and dark plum fruit composition and preparation method thereof, and application of ginger and dark plum fruit composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| CN102697893B (en) | Application of black raspberry extract (BRBE) in preparation of drugs for treating gastric cancer | |
| CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
| CN105232623A (en) | Application of cyclocarya paliurus extract in preparation of medicine for treating stomach cancer | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN104686657A (en) | Formula donkey milk powder with anti-tumor efficacy | |
| CN101474173B (en) | Application of cumarin coumpound Murraya jasminorage ketone in preparing anti-tumor medicament | |
| CN107137416B (en) | A kind of pharmaceutical composition preventing and treating non-small cell lung cancer | |
| CN102861236B (en) | Anti-tumor preparation made of pure traditional Chinese medicines | |
| CN102166336A (en) | Composition of loguat leaves and ginger as well as preparation method and application thereof to preparing toxicity reducing and efficacy enhancing medicines for radiotherapy and chemotherapy of cancers | |
| CN102631409B (en) | Health-care medicine formula with functions of enhancing immunity, alleviating physical fatigue and resisting tumor | |
| CN108186794A (en) | A kind of Chinese medicine composition for treating malignant tumour and its preparation method and application | |
| TW202206090A (en) | Astragalus pharmaceutical composition enhances the use of cancer treatment | |
| CN104069194A (en) | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof | |
| CN109731019B (en) | A composition with chemotherapy synergistic effect comprises components, preparation and application | |
| CN106798892A (en) | A kind of chemotherapy combined antitumor Chinese and its application with Synergy and attenuation effect | |
| CN103169778B (en) | Medicament for treating lung cancer and preparation method thereof | |
| CN101007047B (en) | An antitumor medicine composition and its preparation method | |
| CN105596889A (en) | Antitumor composition containing resveratrol and preparation method of antitumor composition | |
| CN106619870B (en) | Composition for treating digestive system tumor and preparation method thereof | |
| CN103919850A (en) | Pharmaceutical composition and application thereof in preparation of anti-tumor medicament | |
| CN105477068B (en) | Preparation method and application of active site of mulberry branch and leaf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080402 |